Defence Therapeutics (TSE:DTC) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Defence Therapeutics is exploring the use of its Accum technology to enhance the efficacy and prolong the half-life of GLP-1 agonists in treating obesity and related conditions such as type 2 diabetes. The company aims to address challenges like tolerability, injection frequency, and patient compliance, amidst a rapidly growing market for GLP-1 receptor agonists, projected to be worth over US$ 125 billion by 2033.
For further insights into TSE:DTC stock, check out TipRanks’ Stock Analysis page.
